Real-world Experience with New Systemic Agents for Atopic Dermatitis in the Netherlands

Anne R. Schlösser; A. C.M.(Lia) Kunkeler; Dirk Jan Hijnen

doi:10.1016/j.iac.2025.06.008

Real-world Experience with New Systemic Agents for Atopic Dermatitis in the Netherlands

Anne R. Schlösser
, A. C.M.(Lia) Kunkeler
, Dirk Jan Hijnen^*

^*Corresponding author for this work

Dermatology

Research output: Contribution to journal › Article › Academic › peer-review

5 Downloads (Pure)

Abstract

Atopic dermatitis (AD) is a chronic inflammatory skin disease characterized by severe itch, significantly affecting patients’ quality of life. Increased understanding of the underlying pathomechanism has led to the development of effective new systemic treatments, including biologics and Janus kinase inhibitors. However, responses to these new treatments vary among patients, highlighting the need for personalized approaches. This article provides an overview of AD’s epidemiology, pathogenesis, and management strategies, focusing on the effectiveness and safety of new systemic treatments and patient-centered dosing regimens. It also explores future biomarker predictions and discusses new systemic treatments currently in development.

Original language	English
Pages (from-to)	619-633
Number of pages	15
Journal	Immunology and Allergy Clinics of North America
Volume	45
Issue number	4
DOIs	https://doi.org/10.1016/j.iac.2025.06.008
Publication status	Published - Nov 2025

Bibliographical note

Access to Document

10.1016/j.iac.2025.06.008

1-s2.0-S0889856125000529-mainFinal published version, 4.25 MBLicence: Article 25fa Dutch Copyright Act

Cite this

@article{41725b45854d4694a69f57f850a259ad,

title = "Real-world Experience with New Systemic Agents for Atopic Dermatitis in the Netherlands",

abstract = "Atopic dermatitis (AD) is a chronic inflammatory skin disease characterized by severe itch, significantly affecting patients{\textquoteright} quality of life. Increased understanding of the underlying pathomechanism has led to the development of effective new systemic treatments, including biologics and Janus kinase inhibitors. However, responses to these new treatments vary among patients, highlighting the need for personalized approaches. This article provides an overview of AD{\textquoteright}s epidemiology, pathogenesis, and management strategies, focusing on the effectiveness and safety of new systemic treatments and patient-centered dosing regimens. It also explores future biomarker predictions and discusses new systemic treatments currently in development.",

author = "Schl{\"o}sser, \{Anne R.\} and Kunkeler, \{A. C.M.(Lia)\} and Hijnen, \{Dirk Jan\}",

note = "Publisher Copyright: {\textcopyright} 2025 Elsevier Inc.",

year = "2025",

month = nov,

doi = "10.1016/j.iac.2025.06.008",

language = "English",

volume = "45",

pages = "619--633",

journal = "Immunology and Allergy Clinics of North America",

issn = "0889-8561",

number = "4",

}

TY - JOUR

T1 - Real-world Experience with New Systemic Agents for Atopic Dermatitis in the Netherlands

AU - Schlösser, Anne R.

AU - Kunkeler, A. C.M.(Lia)

AU - Hijnen, Dirk Jan

PY - 2025/11

Y1 - 2025/11

N2 - Atopic dermatitis (AD) is a chronic inflammatory skin disease characterized by severe itch, significantly affecting patients’ quality of life. Increased understanding of the underlying pathomechanism has led to the development of effective new systemic treatments, including biologics and Janus kinase inhibitors. However, responses to these new treatments vary among patients, highlighting the need for personalized approaches. This article provides an overview of AD’s epidemiology, pathogenesis, and management strategies, focusing on the effectiveness and safety of new systemic treatments and patient-centered dosing regimens. It also explores future biomarker predictions and discusses new systemic treatments currently in development.

AB - Atopic dermatitis (AD) is a chronic inflammatory skin disease characterized by severe itch, significantly affecting patients’ quality of life. Increased understanding of the underlying pathomechanism has led to the development of effective new systemic treatments, including biologics and Janus kinase inhibitors. However, responses to these new treatments vary among patients, highlighting the need for personalized approaches. This article provides an overview of AD’s epidemiology, pathogenesis, and management strategies, focusing on the effectiveness and safety of new systemic treatments and patient-centered dosing regimens. It also explores future biomarker predictions and discusses new systemic treatments currently in development.

UR - https://www.scopus.com/pages/publications/105014096494

U2 - 10.1016/j.iac.2025.06.008

DO - 10.1016/j.iac.2025.06.008

M3 - Article

C2 - 41136099

AN - SCOPUS:105014096494

SN - 0889-8561

VL - 45

SP - 619

EP - 633

JO - Immunology and Allergy Clinics of North America

JF - Immunology and Allergy Clinics of North America

IS - 4

ER -

Real-world Experience with New Systemic Agents for Atopic Dermatitis in the Netherlands

Abstract

Bibliographical note

Access to Document

Other files and links

Fingerprint

Cite this